Novo Nordisk raises profit forecast for Wegovy as sales of weight-loss drug soar

Highlights

Novo Nordisk, the Danish pharmaceutical company, has raised its profit forecast for the weight-loss drug Wegovy.
Sales of Wegovy have been increasing significantly, with at least 25,000 people in the US starting the drug each week.
Despite falling prices for Wegovy and another drug, Ozempic, Novo Nordisk remains optimistic about its growth.

Opinions

You've reached the end